Day: January 30, 2026

30 January 2026, 08:30 CET The Government of the Republic of Liberia and ArcelorMittal (“the Company”) have signed an amendment to the existing Mineral Development Agreement (MDA), which was yesterday ratified via the Liberian legislative process, extending the duration of the agreement to 2050, with a right to renew for a further 25 years. The agreement solidifies ArcelorMittal’s long-term mining expansion and commitment to Liberia. It also provides for the Government’s desire to make the Tokadeh to Buchanan rail corridor accessible to multiple users. The agreement, alongside the recent inauguration of ArcelorMittal’s iron ore concentration facility at Tokadeh in Nimba County, highlights Liberia’s growing stature as a competitive and strategic hub for mineral development in West Africa. The state-of-the-art concentrator facility is one...

ORION CORPORATION PRESS RELEASE 30 JANUARY 2026 at 9.30 EET                    Orion publishes Financial Statement Release for 2025 and holds a webcast on 12 February 2026 Orion will publish Financial Statement Release for 2025 on Thursday, 12 February 2026 at approximately 12.00 noon EET. The release and related presentation material will be available on the company’s website at www.orionpharma.com/investors after publishing. Webcast and conference call A webcast and a conference call for analysts, investors and media representatives will be held on Thursday, 12 February 2026 at 14.00 EET. A link to the live webcast is available on Orion’s website at www.orionpharma.com/investors. A recording of the event will be available on the website later the same day. Confenrence call can be joined by registering through the following link:...

THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001. The shares of common stock being offered pursuant to the public offering are being offered at a public offering price of $1.30 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering are expected to be $41.6 million, before deducting underwriting discounts and commissions and other offering expenses. The public offering is expected to close on or about February 2, 2026, subject to the satisfaction of customary closing conditions. In addition, Lexicon has granted the underwriters a 30-day option to purchase up to an additional 4,800,000...

AKVA group ASA hereby invites you to the presentation of the Q4 2025 financial results, which will take place as follows: Time: Friday February 13th, 2026, at 10:00 CET. Place: Hotel Continental in Oslo, Stortingsgaten 24/26.In addition to the physical presentation in Oslo, the event will be live streamed:https://qcnl.tv/p/royV7t2x9yGyqldQI0PCFg The presentation will be held in English and registration for the physical presentation can be submitted to abekkeheien@akvagroup.com Dated: 30 January 2026                        AKVA group ASA Web: www.akvagroup.com CONTACTS:Knut Nesse Chief Executive OfficerPhone: +47 51 77 85 00Mobile: +47 91 37 62 20E-mail: knesse@akvagroup.comRonny Meinkøhn Chief Financial OfficerPhone: +47 51 77 85 00Mobile: +47 98 20 67 76E-mail: rmeinkohn@akvagroup.com

Sampo plc, stock exchange release, 30 January 2026 at 8:30 am EET Sampo plc’s share buybacks 29 January 2026 On 29 January 2026, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  8,333 9.44 AQEU    79,549 9.44 CEUX  31,275 9.45 TQEX  91,646 9.44 XHELTOTAL 210,803 9.44  * rounded to two decimals                      On 5 November 2025, Sampo announced a share buyback programme of up to a maximum of EUR 150 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 6 November 2025,...

Data from up to 42 months of treatment reinforce lucerastat’s potential as a first-in-class oral substrate reduction therapy addressing key unmet needs across the Fabry population The company is finalizing the development plan for the optimal regulatory pathway to approvalAllschwil, Switzerland – January 30, 2026Idorsia Ltd (SIX: IDIA) announces that the results of lucerastat treatment over 42-months and the kidney biopsy data will be presented at the 22nd Annual WORLDSymposium™, taking place from February 2-6, 2026. The following two posters will be presented on February 5, 15:30 PST (February 6, 00:30 CET):Lucerastat, an investigational oral substrate reduction therapy in Fabry disease: Kidney biopsy results from the MODIFY open-label extension study (#125, Kiosk 14-B) Lucerastat effect on kidney function in patients with...